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Abstract 
Background: Breast Cancer (BC) is one of the most important causes of death by cancer in the 
world. Cancer mortality is directly related to the inability of curing advanced disease. Much has 
been the effort in the last decades to develop new drugs. 
Precision oncology aims at delivering the most adequate treatment to each patient according to 
the specific characteristics of the disease at each time point. Nevertheless, considering tumor 
heterogeneity, both temporal and spatial, tissue biopsies might be less accurate than new 
emerging techniques such as circulating cell-free tumor DNA (ctDNA) analysis in blood – liquid 
biopsy. It is estimated that 80-90% of advanced cancer patients have genetic alterations that 
could potentially be targeted with a specific drug and some studies suggest that patients treated 
with these targeted drugs might have better outcomes, although there is controversy. 
This is a proof-of-concept study. With this study we aimed to determine: 
1. If ctDNA can be isolated from plasma samples of patients with metastatic BC; 
2. If it is possible to detect specific druggable mutations and amplifications in ctDNA, 
namely: PIK3CA mutation and amplification, AKT1 mutation, AKT2 amplification, EGFR 
amplification, FGFR1 amplification; 
3. If there is an association between genetic alterations detectable in plasma and tumor 
biopsies performed at the same time. 
Methods: This is a single center prospective observational study with sample collection. We 
included patients with metastatic BC (MBC) de novo or after progression or relapse. We also 
included stage III BC patients with advanced unresectable disease. Only patients with clinical 
indication for re-biopsy and who gave consent for biopsy and blood sample collection were 
included. For each patient, analysis of the tumor and blood sample were performed with a 
maximum 8-week interval. 
DNA was extracted from tissue samples and ctDNA was isolated from plasma. Digital droplet 
PCR (ddPCR) was used to detect amplifications and massive parallel sequencing (MPS) was used 
for mutations. We extracted germline DNA (gDNA) from leukocytes to screen for mutations in 
targeted genes, in order to prove a potential somatic origin for the detected mutations. 
Results: We enrolled 2 patients who had undergone previous lines of treatment and progressed. 
While patient 001 had MBC (rebiopsy of a lung metastasis), patient 002 had locally advanced, 
unresectable disease (rebiopsy of the breast).  
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Regarding amplification of the genes tested, we detected an amplification in FGFR1 in patient 
001, both in tissue (8.5-fold increase in copy number) and plasma samples (9.7-fold increase in 
copy number). 
We also detected a PIK3CA mutation in exon 10 (coding exon 9) in patient 002, which is one of 
the most frequent mutations in PIK3CA found in BC [c.1633G>A p.(E545K)]. This mutation was 
detected only in tissue sample and not in ctDNA; this mutation was proven somatic since it was 
not present in the gDNA. 
Conclusions: We succeeded to isolate ctDNA from plasma samples for both patients – proven by 
the finding of the somatic variants. We were able to detect one actionable alteration for each 
patient: FGFR1 amplification was present in both tissue and ctDNA of patient 001. Regarding 
patient 002 a mutation in PIK3CA was detected, although only in tumor tissue sample.  We did 
not find a complete concordance between mutations detected in tumor tissue and plasma 
samples. This might be due to several reasons, either technical or biological. 
 
 
 
 
 
 
 
 
 
 
Keywords: Metastatic Breast Cancer, Precision Oncology, Liquid Biopsies, Druggable mutations 
and amplifications 
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Resumo 
Racional: O cancro da mama é, mundialmente, uma das principais causas de morte por cancro. 
A mortalidade relaciona-se directamente com a incapacidade de curar a doença avançada. Nas 
últimas décadas têm-se empreendido importantes esforços no desenvolvimento de novos 
fármacos. 
A oncologia de precisão almeja providenciar a terapêutica mais adequada a cada doente de 
acordo com as características específicas da doença, em cada momento. Contudo considerando 
a heterogeneidade tumoral, quer temporal quer espacial, as biópsias tecidulares podem ser 
menos precisas que novas técnicas tal como a análise de DNA tumoral circulante no sangue 
(ctDNA) – biópsia líquida. Estima-se que 80-90% dos doentes com cancros avançados 
apresentem alterações genéticas a nível do tumor que poderiam potencialmente ser alvo de 
terapêutica com fármacos dirigidos. Na verdade, alguns estudos sugerem que os doentes 
tratados com fármacos dirigidos tenham melhores resultados em termos de saúde, embora seja 
controverso. 
Este é um estudo de prova de conceito. Com este estudo procuramos determinar: 
1. Se o ctDNA pode ser isolado de amostras plasmáticas de doentes com cancro da 
mama metastático; 
2. Se é possível detectar determinadas mutações e amplificações que possam ser alvo 
terapêutico no ctDNA. Nomeadamente: mutação e amplificação PIK3CA, mutação AKT1, 
amplificação AKT2, amplificação EGFR, amplificação FGFR1; 
3. Se há associação entre as alterações genéticas detectadas no plasma e em biópsias 
tecidulares realizadas simultaneamente. 
Métodos: Este é um estudo observacional prospetivo unicêntrico com colheita de amostras. 
Incluímos doentes com cancro da mama metastático de novo ou após recidiva ou progressão. 
Também incluímos doentes com cancro da mama estadio III com doença irressecável. Foram 
apenas incluídos doentes com indicação clínica para re-biópsia e que consentiram quer a 
colheita de tecido quer de sangue. Para cada doente a análise tumoral e de plasma foram 
realizadas com um intervalo máximo de 8 semanas. 
O DNA foi extraído de amostras de tecido e o ctDNA foi isolado a partir do plasma. Usámos 
Digital droplet PCR (ddPCR) para detectar amplificações e sequenciação massiva em paralelo 
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(MPS) para mutações. Extraímos DNA germinal (gDNA) de leucócitos e analisámos mutações em 
genes algo com MPS. 
Resultados: Foram incluídos 2 doentes que tinham sido submetidos a linhas terapêuticas prévias 
com progressão. Enquanto o doente 001 tinha neoplasia da mama metastática (biópsia de 
metástase pulmonar), o doente 002 tinha doença localmente avançada, irressecável (biópsia da 
mama). O DNA foi isolado das amostras de plasma e quantificado; estava presente DNA em 
ambas as amostras plasmáticas. Foi extraído DNA de amostras congeladas obtidas por biópsia. 
Considerando a amplificação dos genes testados, detectámos amplificação no FGFR1 no doente 
001, quer no tecido (aumento do número de cópias em 8.5 vezes), quer no plasma (aumento do 
número de cópias em 9.7 vezes). 
No doente 002 foi detectada uma mutação no PIK3CA no exão 10 (exão codificante 9), que é a 
mutação mais frequente do PIK3CA encontrada no cancro da mama [c.1633G>A, p.(E545K)]. Esta 
mutação foi apenas detectada na amostra tecidular e não no ctDNA; esta mutação não estava 
presente no DNA germinal isolado a partir de leucócitos, pelo que se comprovou ser somática. 
Conclusões: Foi possível isolar DNA circulante do plasma de ambos os doentes – facto 
comprovado pela detecção de variantes somáticas. Foi possível detectar alterações passíveis de 
ser alvos terapêuticos em ambos os doentes: amplificação do FGFR1 (tecidular e plasmática) no 
doente 001 e mutação do PIK3CA no doente 002 – embora esta tenha sido apenas detectada 
em amostra tecidular. 
Não observamos uma completa concordância das alterações genéticas detectadas no tecido 
tumoral e no plasma. Isto poderá dever-se a motivos técnicos ou biológicos.  
 
 
 
Palavras-chave: Cancro da Mama Metastático, Medicina de Precisão, Biópsias Líquidas, 
Mutações e amplificações alvo 
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1. Introduction 
Cancer is one of the main causes of death worldwide and its incidence is expected to 
increase along with an increase in the median life expectancy.1 Breast cancer (BC) is the most 
common type of cancer among women in most regions of the world and its incidence has been 
increasing, now accounting for about 25% of all new cancer cases in women.1, 2  
Regardless of the worldwide increase in BC incidence, its mortality rates in western 
countries have remained unchanged or even decreased, due to a combination of both early 
detection and improved treatment strategies. Nevertheless, BC is currently the leading cause of 
cancer death in developing countries, as well as the second leading cause of cancer death among 
women in developed countries. It accounted for an estimated 521 900 deaths worldwide in 
2012.1  
BC mortality derives from the inability to cure advanced disease. Nevertheless, much has 
been done in the past decades in which fundamental research has managed to identify several 
molecular mechanisms that are responsible for tumor origin and progression. In parallel, the 
pharmaceutical industry has been developing therapeutic strategies that can block the effect of 
these oncogenic alterations.3 
 
1.1 Precision Medicine and oncology  
The acquisition of characteristics that allow normal cells to progressively evolve into 
neoplastic cells (the hallmarks of cancer), is a multistep process which requires the acquisition 
of somatic abnormalities in the genome.4 Somatic mutations found in cancer cells are usually 
classified according to the consequences they have on the cancer cell, into driver or passenger 
mutations.5 Some somatic mutations confer advantages to the cancer cells and are involved in 
the development of malignant neoplasms. They are, therefore, called driver mutations. These 
types of mutations are implicated in oncogenesis and as they confer an advantage they are 
positively selected.5, 6 Other mutations, however, do not have functional consequences nor 
confer an advantage to cancer cells and are therefore called passenger mutations, which were 
already present in the genome of a cell when driver mutations occurred and can be carried and 
be present in the final cancer, although frequently without functional consequences.5 
Nevertheless, there are other subclasses of driver mutations, such as those that confer 
resistance to cancer treatment. These mutations might already be present in a limited 
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population of cancer cells, not conferring any particular advantage in the absence of a drug. In 
the presence of a specific therapeutic agent however, this resistant set of clones will have a 
selective characteristic and therefore will preferentially expand and be a driver of disease 
progression.5 There is increasing evidence that cancer is not only an heterogeneous but an ever 
evolving entity, either by its intrinsic genomic instability or even by the selective pressure 
exerted by the treatment instituted.7 
Knowledge of the cancer genome at different stages of the disease and how it influences 
cancer progression already has a big impact in cancer management and it is expected to have 
even a greater role in the future, as precision medicine evolves.  
Precision medicine defines a concept in which prevention and treatment strategies take 
individual variability and the idea of clonal evolution into account.8 It is in fact a concept which 
has been used for a long time in simple procedures (such as blood typing for blood transfusions), 
but with the technological advances we have witnessed we will be able to apply it in broader 
settings.8  Similarly, precision oncology is a science that aims at profiling tumors with the goal of 
identifying alterations that can be targeted with therapeutic agents.9 These drugs would 
therefore only be effective if the tumor shows a specific molecular signature. This is already a 
reality for hormonal receptor positive BC patients in whom hormonal therapy has been used for 
over 25 years.3 Another example of precision oncology in BC patients is the use of anti-Human 
Epidermal Receptor 2 (HER2) agents for patients with HER2 amplification, which also lead to an 
improvement in survival.10 However it is widely known that BC harbors a range of genomic 
alterations both in oncogenes or oncosuppressor genes and each could potentially be a target 
for cancer therapy.11 In fact, about 80-90% of advanced cancer patients who were tested seem 
to have genetic alterations that could potentially be actionable, although only a minority of 
patients actually ends up receiving targeted therapy, which is generally given in a clinical trial.9 
12, 13 In fact, BC patients, along with melanoma patients, are those who more frequently have an 
approved targeted drug option for such an alteration, more frequently reported to be in mTOR 
and HER2.12 Nevertheless, in 2016, only nine genomic alterations were routinely assessed in 
metastatic cancer patients of all types in order to make decisions regarding targeted therapy.14 
The development of such drugs is of key importance as several studies suggest that patients 
treated with these targeted drugs might have better outcomes, such as an increase in 
progression free survival although there is some controversy.11, 14, 15  
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1.2 Actionable mutations in breast cancer 
Solid cancers tend to have a higher median number of molecular alterations when compared 
to liquid tumors. Considering solid tumors, BC seems to be associated with a higher number of 
alterations.12 There is a strong correlation between the number of mutations found and factors 
such as age at diagnosis of cancer, cancer histological grade16 and the presence of metastatic 
disease at the time of biopsy.12 
In 2010, Von Hoff et al. proved that it is possible to perform molecular profiling of tumors 
using immunohistochemistry (IHC), fluorescent in situ hybridization assays (FISH) and 
oligonucleotide microarray (MA).15 From all the patients included, 18 (27%) had a breast cancer 
diagnosis. This study showed that 27% of patients who underwent treatment with targeted 
therapy had an improved progression free survival (PFS) when compared to the PFS for the most 
recent treatment regimen, greater or equal than 1.3.15 In the MOSCATO trial, the same outcome 
was evaluated. In this trial 14% (n=135) had advanced BC and 19% of those (n=38) received 
matched treatment. 36% BC patients who received matched treatment for a detected molecular 
alteration also had a greater than 1.3 increase in PFS. The increase in PFS when compared to the 
last regimen received occurred in 33% of patients (95% CI: 26%-39%, p<0.001), regardless of 
tumor type, drug family administered, level of evidence for the target gene molecular 
abnormality and other factors such as year of inclusion in the study or Royal Marsden Hospital 
(RMH) score (prognostic score to evaluate patient’s life expectancy).14  
Many efforts have been done with order to study the molecular profile of solid cancers. 
Most of the studies however include more than one tumor type. In these studies, several 
potentially targetable alterations are commonly described as frequently present. PIK3CA 
mutations and amplifications,11, 14, 17 ERBB2 mutations and amplifications,14, 17 PTEN mutations 
and deletions,14, 17 FGFR1 mutations and amplifications,11, 14 EGFR mutations and 
amplifications11, 14 and NOTCH1/2/3/4 mutations, amplifications or translocations.14 
SAFIR01/UNICANCER is one of such initiatives, which included metastatic BC patients with 
at least a metastasis in a site accessible for a biopsy. Tissue was tested using Comparative 
Genomic Hybridization (CGH) array and Sanger sequencing for both PIK3CA (exons 10 and 21) 
and AKT1 (exon 4). The most frequent targetable genomic alterations identified occurred in 
PIK3CA (25%), CCND1 (19%) and FGFR1 (13%). There were, nevertheless, several other genomic 
alterations which occurred in less than 5% of patients, namely, AKT1 mutations, EGFR, MDM2, 
FGFR2, AKT2, IGF1R and MET high level amplifications (Figure1).11  
4 
  
Figure 1. Distribution of targetable genomic alterations in BC screened patients in the 
SAFIR01/UNICANCER initiative. Adapted from: André, F. et al, Lancet Oncol 2014; 15: 267–74 
 
 
 
Several other molecular profiling initiatives are taking place, including the AURORA 
initiative, by the Breast International Group (BIG) which is recruiting 1300 women with newly 
diagnosed or metastatic breast cancer. The initiative is assessing 411 genes included in a 
commercially available panel by next-generation sequencing (NGS) and RNA sequencing 
(RNAseq).7 Preliminary results are currently available. In an analysis of 41 enrolled patients, 73% 
had at least one clinically actionable mutation and 88% had either an actionable mutation or a 
copy number alteration.18 Patients with actionable mutations can be treated in the context of 
downstream clinical trials. 
 The plasmaMATCH trial is including patients with advanced breast cancer in order to assess 
the safety and activity of targeted therapies in patients with targetable mutations.19 Of the first 
92 patients enrolled, 40 (43.5%) had at least one actionable mutation: 15 had entered a trial and 
16 were being screened for trial entry. No results are yet available regarding outcomes for these 
patients.20 
1.2.1 PIK3CA 
The PI3K (phoshatidulinositol-4,5-biphosphate 3-kinase) family includes eight different 
catalytic subunits, divided into three classes according to both structure and substrate specificity 
(Figure 2).21 
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Figure 2 – PI3K family catalytic subunits, by class (adapted from Lai K, et al. J Clin Pathol 
2015;0:1–5)  
 
PIK3CA encodes the p110α subunit of the class IA of the PI3K family. It is a lipid kinase that 
normally exists as a heterodimer (along with a p85 regulatory subunit). It is generally activated 
by recruitment to the cell membrane which can be triggered by receptor tyrosine kinases (RTK) 
including the Epidermal Growth Factor Receptor (EGFR), insulin receptor and G-protein coupled 
receptor (GPCR) or RAS.21, 22  
 
Figure 3 – PIK3CA pathway (adapted from Knowles M, et al. Nature Reviews Cancer 2014; 15:25-
41)  
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Deregulation of the PI3K/AKT pathway occurs in several different cancer types and results 
mainly in disruption of the cell cycle.23 In fact, the PI3K/AKT is the pathway most frequently 
altered in BC, although its impact appears to be different depending on the specific cancer 
subtype.22, 24 This can occur by various different mechanisms such as the inactivation of PTEN 
with consequently persistent high levels of PIP3 and constitutive activation of the PI3K 
pathway.21, 22 Other alterations, however, have been reported, such as the amplification or 
mutations in PIK3CA which result in PI3K loss of dependency from growth factors.21 In fact, this 
seems to be the most frequent alteration in the PI3K pathway and, after TP53,  PIK3CA is the 
most frequently mutated gene in BC, occurring in up to 40% of all BC patients.24, 25  
PIK3CA shows frequent gain-of-function mutations in exons 9 and 20, the helical and kinase 
domains of PIK3CA, respectively (Table 1).24–26 These mutations might have impact in prognosis 
and seem to correlate with significant relapse free survival in BC patients, especially in the 
progesterone-receptor (PR) positive subgroup.24 More importantly, PIK3CA mutation or 
amplification might impact treatment choice. In fact, when treated with targeted agents (AKT or 
mTOR inhibitors), 25% (4 out of 12) previously treated patients with PIK3CA mutation 
responded.11 Taking this into account, there are currently ongoing clinical trials with mTOR 
inhibitors together with hormone therapy in PIK3CA mutant metastatic breast cancer patients 
(such as the SANDPIPER trial with taselisib, which already showed preliminary results and 
SOLAR-1 which showed benefit of combining alpelisib with hormone therapy in metastatic HR+, 
HER2 negative BC patients with PIK3CA mutations regarding progression free survival).27, 28  
 
Table 1 – Frequently found mutations in PIK3CA in patients with BC 
Exon Location AA position AA change Nucleotide Change Mutation 
frequency 
9 Helical Domain E542 p.(E542K) c.1624G>A 11% 
E545 p.(E545K) c.1633G>A 20% 
p.(E545Q) c.1633G>C <1% 
p.(E545G) c.1633A>G <1% 
p.(E545V) c.1633A>T <1% 
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1.2.2 AKT1  
AKT is a family of serine/threonine kinases, which includes AKT1, AKT2 and AKT3 (also known 
as PKBα, PKBβ and PKBγ, respectively). 
AKT1 is part of the PI3K/AKT pathway. As a downstream mediator of PI3K and as previously 
described, AKT1 is involved in pathways that mediate cell proliferation and survival.29 
AKT1 mutation frequently occurs in amino acid 17 with a substitution of a Lysine by a 
Glutamic acid in the lipid-binding pocket. This E17K mutation causes constitutive activity of 
AKT1, with subsequent downstream activation of mediators of proliferation.30 
Taking this into account, AKT1 inhibitors have been tested both in vitro (in which the growth 
of breast cancer explant models with AKT1E17K mutation was inhibited) and in vivo. In fact, in a 
phase I trial a specific AKT1 inhibitor induced partial responses not only in BC patients, but also 
in ovarian cancer patients with AKT1E17K mutation.30 Other studies have used AKT1 as a potential 
target for breast cancer patients. In the SAFIR/UNICANCER study AKT1 mutations occurred in 
4% of all patients assessed (n=12 patients). Of these only half were treated with AKT1 and/or 
mTOR inhibitors and in 3 out of 6 patients, antitumor activity was seen.11  
 
 
Q546 p.(Q546K) c.1636C>A <1% 
p.(Q546E) c.1636C>G <1% 
p.(Q546P) c.1636A>C <1% 
p.(Q546R) c.1636A>G <1% 
p.(Q546L) c.1636A>T <1% 
p.(D549N) c.1636G>A <1% 
20 Kinase Domain H1047 p.(H1947R) c.3140A>G 55% 
p.(H1947L) c.3140A>T 5% 
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1.2.3 AKT2  
AKT2 is one of three isoforms of AKT, as aforementioned. Its expression in tumors has been 
shown to promote cell motility, invasiveness and even metastasis.31 AKT2 is amplified in several 
cancer types, including BC, in which amplification occurred in approximately 2-2.8% of all 
cases.11, 32 AKT2 activation has been found to interact with the estrogen receptor alpha (ERα) as 
activated AKT2 (either constitutively or by EGRF of insulin-like growth factor-1) promotes 
transcriptional activity of ERα; this activity was not inhibited by tamoxifen and is therefore a 
potential mechanism of resistance to this drug.33 Overexpression of AKT2 was also found to 
correlate with amplification of HER2 receptor.34 
In the SAFIR01/UNICANCER trial patients with AKT2 amplification or AKT1 mutation were 
treated with AKT1 and/or mTOR inhibitors and antitumor activity was found in half of them 
(n=3).11 
 
1.2.4 EGFR  
Epidermal growth factor (EGFR) family is composed of four transmembrane receptor 
tyrosine kinases, including EGFR (also known as HER1 or ErbB1), HER2/ErbB2, HER3/ErbB3 and 
HER4/ErbB4, each of them associated with one or more ligands – although to this day there are 
no known ligands to HER2.35, 36 The four members of this family share a common structure which 
includes an extracellular domain (ligand-binding), an hydrophobic transmembrane region and 
an intracellular tyrosine kinase domain.35 When ligands bind to one of these receptors homo or 
heterodimers form, triggering autophosphorylation of tyrosine residues in the cytoplasm which 
activates the receptors, initiating downstream signaling cascades.35 EGFR family members are 
expressed in various tissues and play important roles in both development, proliferation and 
differentiation.36 Amplification or mutations in EGFR might result in a deregulation of this system 
and are linked with aberrant growth loops and have been implicated in the development of 
several human cancers.36 
There are currently two available classes of drugs targeting EGFR: monoclonal antibodies 
(mAbs) such as cetuximab and panitumumab and tyrosine kinase inhibitors (TKI) such as 
erlotinib, gefitinib, afatinib and osimertinib (Table 2). While mAbs primary action is through 
competitive antagonism which inhibits downstream signaling, TKIs bind to ATP-binding 
intracellular domain of protein kinases, inhibiting subsequent signaling pathways.37 
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In fact, EGFR inhibitors are standard treatments for selected patients with non-small cell 
lung cancer (with EGFR mutations) and colorectal cancer (RAS wildtype).37 
In BC, suppression of EGFR appears to be effective in controlling progression by interfering 
in three distinct mechanisms:37 
1) EGFR suppression was proven to suppress stem cell population in preclinical studies  
2) EGFR pathway suppression enhances apoptosis by stimulating the PI3K/AKT and 
PLC/PKC pathways 
3) EGFR pathway might have an important role in regulating the epithelial-mesenchymal 
transition (EMT) in BC cells as suppression of EGFR reduces the expression of EMT 
markers 
Table 2 – Drugs targeting EGFR and current approvals 
 
EGFR amplification occurs in about 6-26% of BC patients, with different reports showing 
different prevalence. It seems, nevertheless, higher in triple negative breast cancer (TNBC) 
patients, where EGFR amplification can occur in about 60% of the cases.37–40 There is also a 
potential association between EGFR positivity in IHC and worse prognosis, especially in TNBC 
patients.39, 41  
EGFR inhibitors might therefore be relevant targeted therapies for BC patients, especially in 
TNBC.37, 40 In the SAFIR01/UNICANCER study, two patients with EGFR amplification were treated 
with EGFR inhibitors and half of them showed response.11 In fact several anti-EGFR agents have 
been tested in BC, including cetuximab,42 panitumumab,43 gefitinib and neratinib, with 
conflicting results.37 
 
Class Drug Approval 
Monoclonal 
antibodies 
Cetuximab Metastatic colorectal cancer (RAS wildtype); Head and 
neck cancer (localized and metastatic, regardless of 
RAS) 
Panitumumab Metastatic colorectal cancer (RAS wildtype) 
Tyrosine 
kinase 
inhibitors 
Afatinib Metastatic non-small cell lung cancer (EGFR mutated) 
Erlotinib Metastatic  non-small cell lung cancer (EGFR 
mutated); metastatic pancreatic cancer (regardless of 
EGFR mutation) 
Gefitinib Metastatic  non-small cell lung cancer (EGFR mutated) 
Osimertinib Metastatic  non-small cell lung cancer (EGFR mutated) 
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1.2.5 Fibroblast Growth Factor Receptor 1 (FGFR1)  
The fibroblast growth factor receptor family is a family of four transmembrane receptor 
tyrosine kinases (FGFR1-4), which share a significant homology between themselves.44, 45 Their 
structure includes an extracellular domain (ligand-binding), a transmembrane domain and an 
intracellular tyrosine kinase binding domain.44 FGFR5 is another related receptor, but given its 
lack of tyrosine kinase domains it is generally considered to negatively control signaling by 
heterodimerizing with other FGFRs.45, 46 Fibroblast Growth Factors (FGFs) bind to FGFRs, 
originating a complex of FGF, FGFR and heparin sulfate proteoglycans (HSPF).44 Downstream 
signaling occurs as a result of the dimerization of this ternary complex.44 
FGFs and FGFRs have a role in regulating cell proliferation, survival, migration and 
differentiation and through these mechanisms can contribute for cancer development.46, 47 In 
fact, FGFR1 is reported to be amplified in several cancer types such as oral squamous carcinoma, 
ovarian cancer, bladder cancer, rhabdomyosarcoma and breast cancer. Nevertheless, the 
amplification usually has a low incidence.46 In BC, however, FGFR1 amplification occurs in about 
10% of the patients and is one of the most frequently found focal amplifications in this disease, 
although it is predominantly found in ER positive cancers.48 FGFR is, therefore, an appealing 
target for cancer therapy and much research has been done in order to develop drugs to 
accomplish FGFR inhibition.49 These drugs can either be selective FGFR TKI inhibitors or non-
selective FRFR TKI inhibitors.45 The latter inhibit not only FGFR but also several other tyrosine 
kinase receptors (TKRs) such as vascular endothelial growth factor receptor (VEGFR) and the 
platelet derived growth factor receptor (PDGFR), among others.45 They can also be classified by 
their mechanism of action, given that some molecules bind to the intracellular domain (small 
molecule inhibitors) and others bind to the extracellular domain, blocking FGFR dimerization 
(antibodies or peptide inhibitors).49 There are several FGFR inhibitors available nowadays such 
as Regorafenib, Ponatinib, Dovitinib, Nintendanib, Pazopanib, Sunitinib and many others.45 
In the SAFIR01/UNICANCER study, 9 patients with FGFR1 amplification were treated with 
FGFR inhibitors in phase 1 or 2 trials and of the 8  patients assessable for efficacy 25% (n=2) 
showed antitumor activity.11 
  
1.3 The importance of molecular re-characterization of metastatic disease 
Tumors are known to show phenotypic heterogeneity and cancer is a dynamic disease both 
spatially and temporally.50  
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Malignant tumors are a result of the accumulation of several genetic alterations which 
ultimately lead to the activation of oncogenes and inactivation of oncosuppressors. Although 
the exact number of driver mutations required is not completely established and possibly varies 
depending on the disease, studies have suggested that common cancers such as BC require 
about 5 to 7 rate-limiting events.5 Nevertheless, in order to acquire driver mutations, tumor cells 
also undergo genetic alterations which do not confer any form of selective advantage – 
passenger mutations.50 Tumor cell populations harbor an intratumoral heterogeneity which 
results mostly from a combination of the intrinsic genomic instability – a hallmark of cancer – 
leading to an increased mutation rate with hyperproliferation.4, 50 In result of this heterogeneity 
a tumor will naturally have distinct cell subpopulations characterized by different 
tumorigenicity, metastatic potential and sensitivity to therapy.51 
 
Figure 4 – Spatial heterogeneity in a patient with clear cell carcinoma of the kidney; (A) regional 
distribution of somatic mutations (as detected by exome sequencing), grey meaning the 
presence of a mutation and blue the absence of a mutation (B) Phylogenetic relationships of 
tumor regions. (adapted from Gerlinger M, et al, NEJM 2012; 366:883-892)  
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This spatial heterogeneity poses as a problem for clinical diagnosis, since the number of 
samples obtained to pathologically characterize a tumor is limited and there is a possibility that 
the sample obtained is not representative of the tumor or misses a more advanced and 
aggressive region.50 Spatial and temporal heterogeneity also impact therapeutic response 
(Figure 4). Heterogeneity dictates that not all cell populations will be equally sensitive to the 
same therapy. Moreover, differences in tumor vasculature or other microenvironmental 
changes will also contribute to different drug concentrations in specific tumor regions which 
might also contribute to the development of resistance.50 Also, when subjected to selective 
pressure, such as a specific treatment, the expansion of resistant cell clones can occur. These 
cells might already have been present at the beginning of the treatment or might result from 
mutations occurring during therapy which conferred a selective advantage to the cells.50 In fact, 
when we analyze biomarkers currently used to establish treatment of BC patients such as ER, PR 
or HER2, several studies show that there are significant rates of discordance between the 
primary tumor and metastatic disease which range from 3.4% to 60% for ER-negative to positive, 
7.2% to 31% for ER-positive to ER-negative and 0.7% to 11% for HER2.7, 52–55 This discordance led 
to change in management of BC of about 14% of patients in one study, considering the 
treatments available at the time. Nevertheless, the impact of tissue confirmations in OS or time 
to treatment failure (TTF) was not significant in this study.56 When considering, however, the 
possibility of detecting other biomarkers which might lead to new therapies (such as in the 
MOSCATO trial), rebiopsy seems to have an impact at least in PFS.14 In fact a recent study (phase 
II IMPACT trial) which evaluated the impact of pathway targeted agents in patients with 
refractory cancers referred to phase I trials, showed that 1307 of 3743 patients tested had one 
or more alterations and received therapy. The 3 year OS rate doubled in the group which 
received matched therapy when compared to 7% in the group which did not receive directed 
therapy.57 
The recognition of this spatial and temporal heterogeneity lead to the recommendation 
that, at the time of first recurrence, metastatic disease should be biopsied as a way of insuring 
accurate tumor histology regarding biomarkers which will have a clear impact in cancer 
treatment.55  
 
1.4 Potential impact of liquid biopsy 
Liquid biopsy is a less invasive technique of determining biomarkers of early diagnosis or 
relapse, prognosis, monitoring of clinical progression and response to treatment in different 
13 
  
tumor types.58 This is generally done by isolating circulating cell-free tumor DNA (ctDNA) or 
circulating tumor cells (CTCs) in serum or plasma samples, although the blood of a cancer patient 
also carries other tumor-derived materials such as exosomes and circulating tumor RNA 
(ctRNA).59 Nevertheless, several other body fluids might be used such as urine, saliva, pleural 
effusion liquid, cerebrospinal fluid or even stool.59 
 
Figure 4 – Liquid biopsy: advantages of this technique over tissue biopsies regarding tumor 
heterogeneity (from Venesio, T. et al, Pathobiology 2017) 
 
There are several advantages of liquid biopsies when compared to tissue biopsies. Tissue 
biopsies are more invasive techniques, carrying an inherent higher risk of morbidity as well as a 
greater technical complexity in acquiring samples. Lesions might not always be accessible, they 
might be in difficult anatomic locations or in regions were a biopsy could be unsafe such as 
around major vessels, in certain regions of the brain or in certain patients with relevant 
comorbidities.59 On the other hand given the heterogeneity of a tumor which is characterized 
by a mixed population of clones, single site biopsies might not be representative of the overall 
predominant molecular profile or mechanism of resistance for a given patient.  They might also 
provide scarce tumor tissue or tissue which is not suitable for the new sequencing techniques.58 
 Liquid biopsies allow the isolation of a range of tumor components, as aforementioned. The 
information provided by these different components is complementary.59 (Table 3) 
Specifically, ctDNA is known to exist since the 1940s, when cell-free DNA was first detected 
in individuals with cancer.60 ctDNA is a small and variable fraction of total cell-free DNA which is 
14 
  
specifically derived from tumours.59 It is believed that ctDNA is released as a result of both 
apoptosis and necrosis.58, 59 
Given its minimally invasive nature and the ability to provide information about the tumor 
regardless of its heterogeneity, liquid biopsy has been considered a technique with several 
potential applications, from diagnostic purposes, to monitoring of response and resistance to 
therapies, and guidance of therapeutic decisions.61 Liquid biopsies can therefore provide a 
minimally invasive mean to molecularly characterize tumors and, by detecting genetic 
alterations, they can shed light on the potentially targetable mutations and amplifications.62, 63 
 
Table 3 – Comparison between the applications of Exosomes, CTCs and ctDNA (adapted from 
(from Siravegna et al, Nature Reviews 2017) 
“Yes” indicates that the approach is feasible, possible, and/or published studies are available; “No” indicates that the 
application is not feasible and/or no studies are available.  
 
Despite all the potentialities of ctDNA as the ASCO 2018 guidelines state, it currently remains 
investigational in early-stage cancer and with little evidence of clinical validity/clinical utility in 
advanced disease apart from some particular situations, specifically selection of treatment in 
EGRF mutant lung cancer for detection of the T790M variant.64 Even regarding the current most 
frequent use of liquid biopsy, EGFR T790M detection, this  test did not detect the mutation in 
40% of patients with a T790M positive test result in tissue samples.65 Nevertheless many studies 
are being conducted and a rapid evolution in this field is expected with many new indications. 
 
 
 ctDNA/RNA CTCs Exosomes 
Potential to fully recapitulate spatial and temporal tumor 
heterogeneity 
Yes No No 
Assessment of pre/post-analytical variability Yes Yes Yes 
Detection of somatic mutations, InDels, copy-number 
alterations and gene-fusions 
Yes Yes Yes 
Evaluation of methylation patterns Yes Yes Yes 
Analysis of mRNA/miRNA/lncRNA/RNA splice variants Yes Yes Yes 
Cell morphology and functional studies ex vivo No Yes No 
Demonstration of signal colocalization No Yes No 
Proteomics analysis No Yes Yes 
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1.4.1. Technologies to analyze ctDNA 
Although there is a variation depending on tumor type, it is estimated that the number of 
CTCs in circulation is of about 1 cell per 1 x 109 blood cells, in patients with metastatic cancer 
and this fraction is expected to be even lower for patients with localized disease.66 Regarding 
cell-free DNA it is also very rare in peripheral blood: most healthy individuals have less than 25ng 
per mL of blood, but in cancer patients the levels are generally a lot higher.66 Since ctDNA it is a 
minor fraction of cell-free DNA (ranging from less than 0.1% to more than 10% of DNA 
molecules), traditional approaches are not suitable to study these molecules.66   
Other technologies have been developed with this purpose, such as digital PCR (dPCR). 
These techniques have a very low limit of detection (it can be below 0.001%), which is 
mandatory for detection of rare alterations in ctDNA.59, 67 dPCR was first described in 1999, with 
the purpose of detecting small populations of mutant cells – more specifically cells with mutant 
RAS oncogene in the stool of patients with colorectal cancer.68 Nevertheless, dPCR can only be 
used for genetic alterations already known. Massive Parallel Sequencing (MPS) (also known as 
NextGeneration Sequencing, NGS) however, allows the discovery of new genetic changes, not 
only at the time of diagnosis but also to potentially determine mutations which can result in 
resistance to therapy.59 These techniques can be used simultaneously, in a complementary 
fashion, to provide a broader knowledge of the genetic alteration. Sensitivity of techniques for 
detection of ctDNA tends to be higher in metastatic patients, given their higher disease burden. 
Low allele frequency variants are variants present at a frequency below 3% and are 
therefore very difficult to detect by common techniques.69 Conventional MPS for instance has a 
relatively high error rate of sequencers (1 wrong base call in 100-1000 sequenced bases). 
Barcode analysis (found in technology such as the HaloplexHS) allows the detection of low 
frequency variants by aligning reads, grouping read pairs to designed probes based on read start-
stop position. This allows that, for each probe, reads with identical molecular barcode sequence 
are grouped and PCR duplicates are removed, therefore reducing the error rate and allowing 
the identification of unique progenitor DNA fragments (de-duplication).69 With such techniques, 
the accuracy of ctDNA analysis is improved and can eventually be performed even in patients 
with lower tumor burden. 
In conclusion, liquid biopsies are a minimally invasive technique, which can be repeated 
throughout the course of disease without significant morbidity for patients. Liquid biopsies can 
potentially have an impact in therapeutic decisions, especially in advanced disease patients for 
whom therapeutic options are scarce.  
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2. Objectives 
Regardless of the improvements in BC therapy in the last decades, with targeted therapy 
such as pertuzumab and trastuzumab70 and antibody-drug conjugates (T-DM1)71 and 
improvement in hormone therapy efficacy with mTOR inhibitors72 and cyclin inhibitors, BC is still 
one of the main causes of cancer death in the world. There is a need to further develop therapy 
with increasingly less toxic drugs. It is known that roughly one third of patients who undergo 
treatment with targeted therapy in advanced lines have an improved PFS when compared to 
the PFS for the most recent treatment regimen. Nevertheless, one of the main barriers of 
molecular profiling of cancer is the need to perform a biopsy of a metastatic site in order to 
obtain tumor tissue – since it might be difficult to access sites, with potential morbidity 
associated with the procedures. Because analysis of ctDNA by liquid biopsy has the potential to 
overcome these hurdles, our specific objectives were: 
 
1. In the clinical setting: 
a. To evaluate DNA isolation from plasma samples of patients with metastatic BC 
b. To evaluate methodologies to detect specific druggable mutations and 
amplifications in ctDNA, namely: PIK3CA mutation and amplification, AKT1 
mutation, AKT2 amplification, EGFR amplification, FGFR1 amplification 
c. To determine if there is concordance between the mutations and amplifications 
detectable in plasma and tumor biopsies. 
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3. Methods  
3.1 Study design and data source 
This is a single-center prospective observational study with sample collection. Data 
concerning patients treated at Centro Hospitalar Lisboa Norte (CHLN) was retrieved. CHLN is the 
reference-center for treatment of a population of patients of the Lisbon metropolitan area, but 
also of patients from Portuguese-Speaking African Countries, who are medically referred for 
certain cancer treatments not available locally, such as radiotherapy. Our population therefore 
includes not only patients referred to us from primary care and the breast oncology 
multidisciplinary meeting (MDT), but we also medically referred patients from Portuguese-
Speaking African Countries. 
Data collected included: gender, diagnosis date, tumor histology, histological grade, ER and 
PR status, HER2 amplification status, metastatic disease profile. 
 
3.2 Study population 
We included patients with American Joint Committee on Cancer (AJCC) version 7.0 stage III 
unresectable or stage IV histologically or cytologically confirmed BC with 18 years or older. Both 
stage IV patients at diagnosis (de novo) or after progression or relapse could be included. We 
also included stage III BC patients with advanced unresectable disease. 
Only patients with metastatic tissue which could be easily biopsied, with clinical indication 
for rebiopsy and who gave consent for biopsy and blood sample collection could be included.  
For each patient analysis of the tumor and blood sample was performed with a maximum 
8-week interval. 
Exclusion criteria included having a second active malignancy. 
 
3.3 Clinical data collection  
Clinical data was collected at the time of the sample analysis, to ensure the longest follow-
up time possible. 
Data regarding patient characteristics (gender, race, date of birth) were collected. Regarding 
tumor characteristics at diagnosis, we collected date of diagnosis, stage at diagnosis (AJCC 
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version 7.0), histological type, grade, Ki67, hormone receptor status (RE, RP) and HER2 receptor 
status, as well as P53 status. We also collected data regarding initial treatment (intention: 
neoadjuvant, adjuvant, palliative; surgery; radiotherapy). At diagnosis of metastatic disease, we 
collected data regarding location of metastases and number of metastatic sites. Data regarding 
treatment of advanced disease was collected (lines of treatment). 
Regarding rebiopsy we registered date of procedure, as well as tumor characteristics 
previously defined (histological type, grade, Ki67, hormone receptor status, HER2 receptor 
status, as well as P53 status). 
Date of last-follow up or death was also collected. 
 
3.4  Sample collection 
Blood and biopsy samples were collected with an interval of 8 weeks maximum within each 
other, in the absence of specific cancer therapy in this period.  
Biopsy samples were kept as fresh frozen tissue.  
10-15mL of blood was collected in EDTA tubes. Blood samples were processed within 4 
hours of collection. Blood was centrifuged at 1600 x g for 10 minutes at 4° C. Plasma was then 
transferred to a new centrifuge tube and centrifuged at 16000 x g for 10 minutes at 4° C. Cell-
free supernatant was then stored at -80° C. The buffy-coat obtained with this process was 
collected and washed with PBS solution and the supernatant was removed. The dry pellet was 
stored at -80° C.  
 
3.5 Germline DNA extraction from PBMC 
The dry pellet was processed by diluting the cells in 200µL of PBS solution. 20µL of 
proteinase K was added and the mix was vortexed. Then 200µL of ATL buffer was added and the 
solution was pulse-vortexed for 15 seconds. The mixture was then incubated at 56ºC at 10-30 
min. We used QIAmp® blood mini kit as described in de section 3.6 DNA extraction from tissue 
samples.  
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3.6 DNA extraction from tissue samples 
DNA extraction from tissue samples was done using QIAmp® Blood mini kit. For this, tissue 
was fragmented and then an ATL buffer and proteinase K were added. Tissue was incubated 
overnight at 56°C. Then 40 µL of RNAse A was added to each tube. The tubes were than briefly 
vortexed and incubated at room temperature for 2 minutes. 200 µL of ATL buffer was then 
added to the mixture, which was then vortexed and incubated for 10 minutes at 70°C. 
The mixture was then briefly centrifuged and 200µL of ethanol (96-100%) was added. 
Mixture was briefly pulse-vortexed and centrifuged. The content was then transferred to a 
QIAmp Mini spin column and centrifuged at 6000 x g. Solution was washed (buffer AW1 and 
buffer AW2) and then elution was performed according to manufacturer’s instructions. DNA was 
then quantified in Nanodrop, according to manufacturer’s instructions. 
 
3.7 Cell-free DNA extraction from plasma 
Isolation of cell-free DNA was done using MagMAX™ cell-free DNA isolation Kit according to 
manufacturer’s instructions. Total DNA quantification was performed using Invitrogen™ Qubit® 
dsDNA HS Assay Kit, according to manufacturer’s instructions. 
 
3.8 ddPCR 
Droplet digital polymerase chain reaction (ddPCR™) is a method that provides high-precision 
quantification of nucleic acid target sequences.  
Probes were selected from Bio-Rad for copy number variation (CNV) analysis for AKT2, EGFR, 
FGFR1 and PIK3CA. Probe assays consisted of unlabeled PCR primers and a dual labeled 
fluorescent probe. 
Droplets were generated using a probes and a ddPCR supermix, according to manufacturer’s 
instructions, and loaded to a DG8™ cartridge for a QX200 droplet generator. Then 70µL of 
droplet generation oil was transferred to the bottom wells of the same DG8™ cartridge. A gasket 
was attached across the top of the cartridge and it was placed in the droplet generator. 
After generating the droplets in the cartridge, the droplets at the top wells were pipetted 
into a PCR plate which as then sealed with Bio-Rad PX1™ PCR plate sealer and pierceable foil 
heat sealer. The plate was then placed in a thermal cycler for PCR, for 40 cycles. After PCR the 
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plate was left overnight at 10°C in the thermal cycler. Droplets were then read by placing the 
PCR plate in a QX200 droplet reader and using by Quantasoft™ software. CNV was determined 
by calculating the ratio of the target molecule concentration to the reference molecule 
concentration, times the number of copies of the reference species in the genome (Figure 5). 
The error bars on a copy number estimate were the 95% confidence interval of this 
measurement. 
 
Figure 5 – Copy number variation determination formula 
CNV=  
𝐴
𝐵
×𝑁𝑏 
A= Concentration of target species; B= concentration of reference species; Nb= number of copies 
of reference loci in the genome 
 
CDH1 (PIK3CA and EGFR) and PTEN (AKT2 and FGFR1) genes were used as reference for 
quantification. Target and reference assays were designed with different probe fluorophores. In 
this case AKT2, FGFR1 and CDH1 had FAM probes and PIK3CA, EGFR and PTEN had HEX probes. 
 
3.9 Library preparation using HaloplexHS followed by MPS 
HaloplexHS is a high sensitivity amplicon based targeted deep sequencing method. It 
promotes incorporation of molecular barcodes in the DNA library therefore allowing the 
identification of duplicate reads and improving base calling accuracy even at low allelic 
frequencies. It allows for the detection of mutations present at below 1% allele frequency in 
samples which are genetically heterogeneous. This kit was selected given that it was the only 
commercially available kit incorporating barcode technology at the time. 
The fluorometry-based Qubit dsDNA HS assay kit was used to determine de precise DNA 
concentration for each sample. Genomic DNA was digested with restriction enzymes to create 
a library of gDNA restriction fragments, according to manufacturer’s instructions.  Digested DNA 
was then hybridized to HaloplexHS probes using a custom panel. The hybridization buffer was 
removed and circularized fragments were ligated. Target DNA was captured and PCR was 
performed to purify the amplified target library. We then validated enrichment and quantified 
enriched target DNA. All steps were performed according to manufacturer’s instructions.  
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MPS, also called next-generation sequencing or deep sequencing, is a form of DNA 
sequencing technology which performs sequencing of millions of small DNA fragments in 
parallel, providing high in depth accurate data, as every base in the genome is sequenced 
multiple times. Bioinformatics analysis maps the individual reads to the human reference 
genome and manages to piece together these fragments. 
MPS was performed using MiSeq® system. Libraries were denatured and diluted. Afterwards 
the libraries were loaded onto the reagent cartridge and the sequencing run was set up. 
 
3.10 Statistical Analysis 
Statistical analysis was performed to detect the rough concordance rate between plasma 
and tissue detection of amplifications and mutations. This was done by using Microsoft Excel 
from Microsoft Office Professional Plus 2016. 
We also determined Cohen’s Kappa to determine interrater agreement, using STATA 14.2 
software (StataCorp LP, TX). Cohen’s Kappa is a statistical test which aims to define interrater 
agreement as the propensity of two or more raters (or, in this case, techniques) to, 
independently from each other, classify a given subject (in this case a gene) into the same 
predefined category. 
 
3.11 Bioinformatic analysis 
Bioinformatic analysis was performed using Trim galore, a wrapper tool which trims 
adapter sequences and low quality bases/reads, allowing an efficient quality control check of 
high throughput sequencing data.73 Agilent Genomics NextGen Toolkit (AGeNT) software 
module was used to process the molecular barcode information obtained from HaloplexHS to 
flag and remove molecular barcode duplicates.74 We also used FastQC software since this is a 
quality control tool for high throughput sequence data which summarizes read quality by 
position and gives information about adapter content in sequences along with other aspects.75 
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4. Results  
4.1 Patient characteristics 
We enrolled two patients with BC who had undergone previous lines of treatment and 
progressed. Patients’ characteristics are listed in table 4.  
 
Table 4 – Patients’ characteristics at diagnosis and at re-biopsy 
Patient 001 002 
Diagnosis Re-biopsy Diagnosis Re-biopsy 
Age 28  32 51 51 
Stage IIB metastatic IIIB unresectable 
Histology Carcinoma NST Carcinoma NST Carcinoma NST Carcinoma NST 
Grade 2 3 2 3 
Ki 67 High 80% 42% 90% 
ER Strong Weak (<1%) Weak (15%) Weak (<5%) 
PR Weak Moderate (<1%) Moderate (60%) Moderate (70%) 
HER2 Not amplified Not amplified Not amplified Not amplified 
P53 Positive Positive Negative Positive 
ER – Estrogen Receptor; PR – Progesterone Receptor; HER2 – Human epidermal receptor 2; NST 
– No special type  
4.1.1 Patient 001  
Patient number 001 was a 28-year old caucasian woman at diagnosis, who initially presented 
with stage IIB BC in 2011. Histology revealed a carcinoma NST, grade 2, luminal B-like tumor. 
Patient underwent neo-adjuvant chemotherapy and surgery (mastectomy with axillary lymph 
node dissection) with partial response (ypT1ypN0). Adjuvant hormone therapy with tamoxifen 
was initiated.  
Patient relapsed in June 2013, with bone metastases and started another hormone therapy 
line (goserelin with letrozole) together with a bone modifying agent (zoledronic acid). Due to 
disease progression in February 2014 she started chemotherapy with capecitabine. In January 
2015, due to bone, lymph node and lung progression chemotherapy was changed to paclitaxel 
which she received until April 2015, when disease progressed. At this point patient underwent 
re-biopsy (table 3), in a lung metastases. Chemotherapy was again changed to gemcitabine with 
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cisplatin, but patient progressed with de novo hepatic metastases and increase in number and 
size of lymph node, lung and bone metastases in October 2015 and started vinorelbine. She 
underwent two further lines of chemotherapy. Patient was deceased in December 2015. 
 
4.1.2 Patient 002 
Regarding patient 002, she was a 51-year old black woman from Guinea Bissau, 
medically evacuated to Portugal in order to receive treatment for a locally advanced tumor of 
the right breast. She presented initially with stage III inoperable BC. Histology revealed a 
carcinoma of no special type (NST), luminal B-like (ER and PR positive, HER2 FISH 2+, not 
amplified by dual-color dual-hapten brightfield in situ hybridization [DDISH]). She underwent 
neoadjuvant chemotherapy with doxorubicin and cyclophosphamide for four cycles with 
response but progressed on neo-adjuvant paclitaxel, with extension to the chest wall, edema of 
the skin, homolateral axillary progression with marked lymphedema. At this point the patient 
remained with stage III inoperable disease. Breast lesion was re-biopsied (table 3) and the 
patient started chemotherapy with vinorelbine and capecitabine with local symptomatic 
progression both in breast and lymph nodes.  Chemotherapy was changed to carboplatin and 
gemcitabine but patient was lost to follow-up, since she decided to return to her home country. 
 
4.2 DNA isolation from plasma samples of patients with metastatic BC 
Blood samples of the patients were collected within an 8 week-interval regarding the 
collection of tissue samples. Samples were processed and stored and DNA from tissue samples 
and DNA were isolated as previously described. After isolation, total DNA quantification was 
performed using Invitrogen Qubit dsDNA HS Assay Kit and results are shown in table 5. 
Table 5 – DNA concentrations obtained from plasma samples provided by patients with 
metastatic BC 
Patient ID Sample type ctDNA concentration (ng/µL) 
001 Plasma 2.89 
Tissue 9.93 
002 Plasma 0.635 
Tissue 15.4 
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The DNA concentration obtained was higher in samples obtained from tissue than 
plasma samples, as expected, although the difference was not statistical significant (p=0.121). 
Nevertheless, it was possible to isolate DNA from both sets of samples, for both patients. The 
DNA concentration in the plasma was higher for patient 001 when compared with patient 002. 
On the other hand, DNA concentration extracted from tissue-samples was higher for patient 
002. 
 
4.3 Quality Control analysis 
 The number of reads obtained from the tissue sample was significantly higher for tissue 
sample (when compared to the plasma sample) in patient 002 but not for patient 001. When 
considering the percent of reads with adapter, it inversely correlates with the overall fragment 
distribution of the library; a higher percent with adapters was detected in the plasma sample 
from patient 002 indicating a small fragment distribution (Table 6). Regarding patient 001, both 
plasma and tissue had a high percent of reads with adapter, although this was higher for the 
plasma sample.  
Read  counting might be complicated by amplification bias (which results from the 
preference of the PCR in reproducing reads of different lengths and compositions), although 
there are other sources of read duplication such as sample coincidence which are more likely to 
be present when the depth of sequencing is high such as in our sample.76 The percent of 
deduplicated reads relates with the coverage of the target sequence, with a low level of 
duplication indicating a very high level of coverage of the target sequence. In this case, the 
percent of deduplicated reads was higher for tissue samples in both patients, when compared 
to plasma samples, meaning tissue samples had a lower duplicate rate and therefore, probably 
a higher coverage. 
Table  6 – Quality control analysis 
 
 Sample type Number of 
reads 
Percent with 
adapter 
Deduplicated 
reads 
Percent of 
deduplicated 
001 Plasma 809140 87.40% 461336 57.02% 
Tissue 761986 75.20% 605646 79.48% 
002 Plasma 568313 78.52% 158327 27.86% 
Tissue 2012715 62.02% 1232443 61.23% 
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4.4 Determination of specific druggable mutations and amplifications in 
tissue samples and ctDNA 
4.4.1 PIK3CA, AKT2, EGFR and FGFR1 amplification  
After the quantification of DNA, we determined CNV by ddPCR. The ddPCR results are 
expressed as the ratio between the number of copies of a given gene and the number of copies 
of the reference gene, as previously described (Figure 5). 
Patient 001 (Figure 6) did not show amplification of PIK3CA both in tissue sample (ratio of 
2.6) and plasma (ratio of 2.3). Regarding patient 002 (Figure 7), there was also no amplification 
either in tissue sample (ratio of 3.0) or in plasma (ratio of 2.6). 
 
Figure 6 – Copy number variation normalized to reference sample in patient 001 in plasma and 
tissue DNA. 
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Figure 7 – Copy number variation normalized to reference sample in patient 002 in plasma and 
tissue DNA.  
 
There were no differences in CNV when comparing AKT2 with reference samples, both in 
plasma and in tissue, for both patients. Patient 001 had a CNV ratio of 2.2 in tissue and 3.1 in 
blood. Regarding patient 002 the CNV ratio was 2.4 in tissue-sample and 2.5 in plasma. 
Regarding EGFR, there was also no evidence of amplification of this gene both in patient 
001 (ratio of 2.8 in tissue and 3.8 in the plasma) and in patient 002 (ratio of 2.9 in tissue and 2.8 
in the plasma sample). 
An FGFR1 amplification was detected in patient 001, both in tissue and plasma samples, 
with a 9.7-fold increase in copy number when compared to the reference sample in the plasma 
and an 8.5-fold increase in copy number in tissue-sample (Figure 8). Regarding patient 002 
FGFR1 was not significantly increased when compared to the reference sample, both in plasma 
(ratio of 2.2) and in tissue (ratio of 2.4). 
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Figure 8 – FGFR1 in patient 001 (A) 2-D plot of droplet fluorescence in tissue sample (B) 2-D plot 
of droplet fluorescence in blood-sample. Grey dots refer to double negative droplets (negative 
FGFR1 and negative PTEN); blue dots refer to droplets positive for FGFR1 and negative for PTEN; 
orange droplets are positive for PTEN and FGFR1 and green droplets are positive for PTEN and 
negative for FGFR1.  
 
  
 
 
 
 
 
 
 
 
 
 
4.4.2 PIK3CA and AKT1 mutation 
 
 
4.4.2 AKT2 and PIK3CA mutations 
Regarding potential mutations in PIK3CA, the most frequently found are gain-of-function 
mutations in exon 9 and exon 20 (the helical and kinase domains of PIK3CA), as previously 
described. In these two patients we found one mutation in patient 002. Nevertheless, other 
genetic alterations were present (Table 7). 
In patient 001, ctDNA showed the presence of three SNVs in PIK3CA which were all 
germline: rs3729674 , rs2699896  and rs6443625.  While the second SNV has a known benign 
significance according to the standards and guidelines for the interpretation of sequence 
variants,77 the other two SNVs have no known clinical significance. In comparison, in tissue 
sample rs3729674 was also found but the other SNVs were not detected. On the other hand, 
another SNV was detected in tissue-sample: rs41273619 and has a benign significance.77 All the 
A 
B 
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SNVs detected both in ctDNA and tissue samples were germline since they were present in the 
DNA isolated from leukocytes. 
Regarding AKT1 its mutation frequently occurs in amino acid 17 with a substitution of a lysine 
by a glutamic acid in the lipid-binding pocket, causing a constitutive activation of AKT1, with 
subsequent downstream activation of mediators of proliferation. This mutation was not 
detected in any of the patients, along with other potential mutations. Nevertheless, three SNVs 
were detected in ctDNA: rs3730346, rs2494748 and rs2494749. None of this SNV have a known 
significance (either pathogenic or benign) in BC patients and they were all detected in germline 
DNA. The significance of these mutations was classified with the functional analysis through 
hidden Markov models (FATHMM). This is a computational technique which produces 
predictions regarding the significance of single nucleotide variants and its ultimate goal is to 
determine which mutations are pathogenic.78 The functional score is presented as a single p-
value, ranging from 0-1 with scores equal or higher than 0.7 being classified as pathogenic and 
scores equal or below 0.5 as neutral (all others are unknown).79 
Table 7 – Mutations/SNVs in patient 001 and 002 
Patient 
PIK3CA AKT1 
ctDNA Tumor DNA gDNA Meaning ctDNA Tumor DNA gDNA Meaning 
001 rs3729674 rs3729674 rs3729674 Unknown rs3730346 ND rs3730346 Unknown 
rs2699896 ND rs2699896 Benign rs2494748 rs2494748 rs2494748 Unknown 
rs6443625 ND rs6443625 Unknown rs2494749 rs2494749 rs2494749 Unknown 
ND rs41273619 rs41273619 Benign - - - - 
002 rs3729674 rs3729674 rs3729674 Unknown rs1130233 rs1130233 rs1130233 Pathogeni
c score 
0.72 
FATHMM 
rs2699896 rs2699896 rs2699896 Benign rs3730346 rs3730346 rs3730346 Unknown 
rs2230461 rs2230461 rs2230461 Benign? rs2494749 rs2494749 rs2494749 Unknown 
rs6443625 rs6443625 rs6443625 Unknown ND rs34670300 rs34670300 Unknown 
ND rs104886003 ND Pathogenic 
(Path score 
0.97 
FATHMM) 
- - - - 
ND – not detected; gDNA – germinal DNA; FATHMM – Functional analysis through Hidden 
Markov models 
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In patient 002 we detected 3 different SNV in ctDNA regarding AKT1: rs1130233, rs3730346 
and rs2394749. None of the SNV have a known pathological meaning. A fourth SNV was found 
only in tissue sample, rs34670300 and all four were present in gDNA. None of the SNV detected 
have a known pathological significance. 
In PIK3CA there were 4 detected SNV, 2 with unknown meaning (rs3729674 and rs2699896), 
2 with benign or probably benign significance (rs2230461 and rs6443625). There was also a 
mutation detected, PIK3CA c.1633G>A, p. (E545K) (rs104886003), which was only found in the 
tissue sample. This mutation occurred in cytogenetic location 3q26.32, which occurs in exon 10 
(coding exon 9) encoding the catalytic subunit alpha of PIK3CA. In this case a guanine was 
substituted by an adenine, which conditioned a substitution of a glutamic acid to lysine. This is 
one of the most frequent mutations in PIK3CA detected in breast cancer.22 Since this mutation 
is not present in gDNA, we can infer that it is a somatic mutation present in tumor tissue instead 
of a germline mutation. 
 
4.5 Concordance of results between plasma and tumor biopsies 
 
4.5.1 Association between amplifications detectable in plasma and tumor biopsies 
There was an overall concordance between the results obtained in tissue samples and blood 
samples. Only one amplification was detected in a plasma sample, namely in patient 001, and 
the amplification was present also in the tissue sample.  
Cohen’s Kappa coefficient for agreement was calculated as previously described. Regarding 
amplification of genes, there was a 100% concordance between blood and tissue detection in 
the overall sample (Kappa coefficient of 1.00), which did not vary between patients or in 
different genes analyzed. 
 
4.5.2 Association between mutations detectable in plasma and tumor biopsies 
There was only one mutation in the genes analyzed by MSP, in the DNA extracted from tissue 
samples. No mutation was detected in ctDNA. Nevertheless, MPS detected other alterations, 
namely single nucleotide variations (SNV) in both samples, and we used these alterations 
together with the mutation found to detect the concordance ratio between plasma and tissue 
samples. 
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Regarding patient 001, there was a concordance of 25.00% and 66.67% in SNV detected in 
tissue versus blood (PIK3CA and AKT1, respectively), while in patient 002 this concordance was 
higher, of about 75-100% (AKT1 and PIK3CA, respectively).  
Regarding Cohen’s Kappa coefficient there was an overall agreement of 62.50% (Standard 
Error of 0.25) between blood and tissue detection of SNV. Cohen’s Kappa was -0.23 when 
considering both samples. The rate of agreement was higher for patient 002 (77.78%), kappa 
not available, than from patient 001 (42.86%, kappa coefficient of -0.27) and higher for AKT1 
(71.43%, kappa=-0.17) than from PIK3CA (55.56%, kappa=-0.28). 
There was, therefore a substantial rough agreement rate between tissue and blood samples 
for both the detection of amplifications and SNV. Nevertheless cohen’s kappa coefficient was 
low when considering the rate of agreement of SNVs. Only one actionable mutation in the genes 
analyzed was present in these patients. 
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5 Discussion 
 
BC is still one of the most important causes of death by cancer worldwide and its lethality is 
directly related to our inability to cure advanced disease.1 Precision medicine is a somewhat 
recent concept which acknowledges variability both within patients and also within the same 
tumor – as tumors are heterogeneous both spatially and temporally.7, 50 Specifically precision 
oncology aims at determining new targets for each patient, taking into account both patient and 
tumor variability and evolution.8 In order to be able to characterize a tumor and considering its 
spatial heterogeneity, tissue biopsies might not be the best technique and new strategies are 
emerging, such as ctDNA analysis in plasma, a form of liquid biopsy.59 
With this study we aimed to determine if actionable alterations in tumor DNA could be 
accurately detected by using liquid biopsy. For this, we analyzed BC patient samples in order to 
determine if ctDNA could be isolated from plasma samples, if specific actionable mutations and 
amplifications could be detected in plasma ctDNA and if there was an association between the 
druggable mutations and amplifications detectable in plasma and tumor biopsies performed at 
the same time. 
Although we could detect ctDNA in plasma samples from both patients, the amount of 
ctDNA isolated was higher for patient 001. This patient had a higher cancer burden, with visceral 
metastases in the lung and liver, while patient 002, although incurable due the extension of the 
disease, only had local invasion. Other studies support the hypothesis that the probability of 
ctDNA detection is higher in patients with higher tumor burden.80 One study reported that 
plasma ctDNA could be detected in over 75% of patients with advanced BC in comparison to 
about 50% of patients with localized BC.81 Additionally patient 001 had also received more prior 
lines of chemotherapy. In other studies, having received more lines of therapy was associated 
with a higher probability of detecting certain mutations in plasma ctDNA.65 This could be due to 
the number of previous lines acting as a surrogate marker for disease burden or could relate to 
a potential effect of ctDNA shedding from tumor cells promoted by chemotherapy.65 
Regarding tissue-sample DNA, the amount isolated was higher for patient 002, in whom a 
breast tumor biopsy was done when compared to patient 001, who underwent a lung metastasis 
biopsy.  
One of the most frequently found alterations in BC is in PIK3CA, which can be both mutated 
(more frequently) or amplified.11, 25 Nevertheless, other alterations are also relatively frequent, 
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such as FGFR1 amplification,11, 48 AKT1 mutations,11, 82 EGFR37, 38 and AKT2 amplifications.11, 32 All 
of these mutations or amplifications have directed therapies available, some of them in use for 
other diseases. Therefore, the presence of such druggable mutations and amplifications in 
patients with advanced BC might be of particular relevance, since these alterations can be 
targeted and mean an additional line of treatment available for a disease, which remains, to this 
day, incurable. 
Here we show that it is possible to isolate ctDNA from plasma samples (Table 5) from 
patients with advanced BC. After DNA isolation from plasma and tissue samples we were able 
to determine amplifications in specific actionable mutations. There was a correlation of 100% 
between amplifications determined in plasma and tissue samples. In this studies, only an FGFR1 
amplification was detected (one patient). FGFR1 amplification is detected in about 7.5-17% of 
BC considering all subtypes, although it is in fact more common in luminal B-type BC.45, 48 There 
is an association between FGFR1 amplification and worse prognosis in BC patients.83–85 This 
association seems to be better established for ER positive BC, such as in the patient studied. It 
is also known that patients with FGFR1 amplification might benefit from FGFR inhibitors. In fact, 
TKIs (both FGFR selective and non-selective) are currently available for FGFR inhibition and other 
molecules such as monoclonal antibodies and FGF-ligand traps are under development.45 
Moreover, there is one study reporting that lucitinib (a non-specific TKI) had an overall response 
rate of about 50% in BC patients with FGFR1 amplification.85 
The rate of actionable mutations detected is different in different trials, but large 
retrospective studies have described as much as 80-90% of patients will have one of these 
mutations.9 In this study, we only detected one actionable mutation in PIK3CA, considering the 
genes we had pre-selected as potentially relevant to shape future treatment of these patients 
(namely PIK3CA and AKT2). Nevertheless, we were able to detect SNVs present in both blood 
and tissue samples for both the patients, although the Cohen’s kappa coefficient was low (less 
than 0.40) and the rate of agreement between detection in plasma and tissue was, therefore, 
lower than it is desirable. Considering that tumor mutations had a lower frequency than 
expected, there are a number of reasons we need to consider. For instance, the amount of 
ctDNA isolated is key for the success of this technique. In fact, if there is not enough ctDNA due 
to a low plasma concentration (which might be an issue particularly for patients with lower 
tumor burden) we might not be able to detect certain mutations or amplifications in ctDNA. 
Nevertheless we cannot exclude technical issues. In this case, the kit we used for ctDNA isolation 
(HaloplexHS) was the only commercially available kit incorporating barcode technology at the 
time and thus the only available kit with enough sensitivity to detect ctDNA. Nevertheless, given 
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the degree of DNA degradation (given by fragment size distribution) this technique is not 
particularly appropriate to use with MPS. We also have to consider that even in tests currently 
approved for clinical use (EGFR T790M mutation determination in ctDNA), the rate of false 
negatives is still high enough to warrant a tissue-sample test if the mutation is not found.86 
 
Considering patient 001, in PIK3CA we detected one SNVs of unknown significance in both 
plasma and tissue sample. The other three SNVs detected were either only detected in the 
plasma (one classified as benign and other as unknown clinical significance) or only in the tissue 
sample (a SNV classified as benign). In AKT1 on the other hand we detected three SNVs of 
unknown significance in the plasma sample, two of them were also detected in the tissue 
sample.  
Patient 002 presented with four SNVs in PIK3CA which were detected both in ctDNA (two of 
unknown significance and two benign) and in tissue samples. There was nevertheless a mutation 
known to be pathogenic which was only detected in the tissue sample. This is contrary to what 
we expected, that liquid biopsies, given their ability to represent tumor heterogeneity, would 
present at least with the same number of alterations as tissue samples. The mutation detected 
in the tissue sample in patient 002 was a change in the amino acid residue at the position 545 in 
the PI3K catalytic subunit alpha form in coding exon 9, with Glutamic acid being substituted by 
Lysine (p.(E545K)). This is the second most frequent hotspot cluster in PIK3CA gene (table 1).22 
Mutated PIK3CA proteins have an increase in the enzymatic activity of p110α.26 It is believed 
that the Glutamic acid to Lysine creates a difference in charge which has a conformational effect, 
causing an alterations in enzymatic activity.26 The increased activity of PI3K promotes 
downstream activation of AKT which will therefore promote intracellular processes such as 
proliferation, which is a selective characteristic for cancer cells.87 Patient 002 therefore had an 
actionable mutation detected in the tissue-sample and could, eventually, be a candidate to 
therapy with AKT or mTOR inhibitors in a clinical trial, as reported in the SAFIR01/UNICANCER.11 
The concordance rate of ctDNA SNV detection was higher for patient 002, although lower 
concentrations of ctDNA were detected in this patient; Cohen’s kappa was not available. From 
a clinical standpoint, patient 002 had a stage III inoperable disease, and the disease burden was 
relatively low, as progression was evident only in the breast and axilla. Also this patient had a 
follow-up time of about 5 to 6 months since diagnosis until the time she was re-biopsied. Patient 
001 on the other hand had a higher burden of disease, with bone, lung, liver and lymph node 
metastasis and a follow-up time of about 45 months from the time of diagnosis and at least 22 
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months of known metastatic disease. In this patient we expect higher heterogeneity of the 
tumor cells which can relate to a lower concordance rate between alterations detected in blood 
and in tissue. Nevertheless, we did not find any mutation in patient 001 in the target genes, but 
rather one mutation was found in patient 002. 
Overall, there was a higher detection of SNVs in the plasma sample than in the tissue sample 
for patient 001, but not for patient 002, in whom in fact we detected more SNVs in the tissue 
samples than in ctDNA. This could be due to lower amounts of ctDNA isolated from the plasma 
in patient 002. All the SNVs detected in tumor DNA (isolated from tissue or blood) were also 
present in germline DNA. We can assume that the quality of the samples influences the ability 
to isolate ctDNA. A potential explanation for a higher SNV detection in ctDNA in patient 001 
would be the high burden of disease, with several different metastatic sites contributing to the 
ctDNA isolated, and a higher ctDNA concentrations. Given that all SNVs were also present in 
germinal DNA, tumor heterogeneity, with different sites of metastatic disease possibly showing 
a different phylogenetic evolution, although sharing a series of genetic alterations (Figure 4),66 
is probably not the cause for a higher SNV detection in ctDNA in patient 001.  
On the other hand, patient 002 showed a mutation in tissue-biopsy, which was not present 
in ctDNA. This does not necessarily mean that the mutated cells were not present in the blood 
sample, but might in fact be related to the amount of cells with this specific mutation. It is 
possible that the cells presenting with PIK3CA E545K were minor clones in circulation. In this 
case the allele frequency was 26% in the tissue sample. On the other hand, given the known 
pathogenic significance of this mutation in cancer we expected that this could be a driver 
mutation and would, therefore be detected in the blood.88 We should also consider the 
possibility of a false negative. In fact, other studies using ctDNA to detect actionable mutations, 
namely EGFR T790M mutation in patients with advanced non-small cell lung cancer, report that 
the plasma test (cobas EGFR mutation test v2) did not detect the mutation in 40% of patients 
with a T790M positive tissue test result.65 Of note that in this study cobas plasma test was 
compared with MPS and showed positive and negative agreements of over 90%. Although 
currently it is recommended to test for the EGFR T90M mutation in the plasma, if negative and 
given the rate of false negatives, it is still recommended to test for this mutation in a tissue-
sample. In this case, it is also recommended to treat with osimertinib, regardless of presenting 
the T790M mutation only in the tissue sample.86 Therefore the absence of detection of the 
PIK3CA mutation in ctDNA might in fact be a limitation of the technique used. In fact, since all 
SNVs (both detected only in ctDNA and only in tissue sample DNA) were germinal alterations, 
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we can infer that further technical improvements are needed both for ctDNA and tissue DNA 
isolation and processing. 
 
6 Conclusion and future perspectives 
In the last decade oncology has evolved in order to deliver an increasingly personalized care. 
There is an increasing acknowledgement that cancer is a heterogeneous disease and even within 
the same location or histology type there are several genetic markers which can not only relate 
to a specific prognosis but also predict response to specific therapies. Both lung and breast 
cancer are paradigmatic examples of how personalized medicine can impact the treatment and 
prognosis in oncology with patients with different molecular profiles being treated with 
completely different therapies. As evolution continues, more trials prove that targeting specific 
pathways in patients with refractory cancers impacts outcomes and further personalized care 
will probably be increasingly available in the future.89 
It is likely that liquid biopsies will have an important impact in tumor profiling, as they take 
into account fundamental tumor characteristics such as temporal and spatial clonal evolution. 
At the same time they have a reduced risk of morbidity for the patient when compared to tissue 
biopsies. Nevertheless, ctDNA analysis remains, to this day, investigational in early-stage cancer 
and with little evidence of clinical validity/clinical utility in advanced disease (apart from the 
previously referred situations), although many studies are being conducted and a rapid 
evolution in this field is expected.64  
Regarding this study, ctDNA isolation from plasma samples proved feasible. We were also 
able to detect a druggable genetic alteration in both tissue and plasma. However, further studies 
are needed to improve accuracy of ctDNA analysis. 
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